

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GLAXOSMITHKLINE PLC</u> (Last) (First) (Middle) <u>980 GREAT WEST ROAD</u> (Street) <u>BRENTWOOD X0 TW8 9GS</u> <u>MIDDLESEX</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/11/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>Decibel Therapeutics, Inc. [DBTX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock	458,487	(1)	I	See footnote ⁽⁴⁾
Series C Preferred Stock	(2)	(2)	Common Stock	247,324	(2)	I	See footnote ⁽⁴⁾
Series D Preferred Stock	(3)	(3)	Common Stock	327,852	(3)	I	See footnote ⁽⁴⁾

Explanation of Responses:

- The Series A Preferred Stock is convertible into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election and automatically upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- The Series C Preferred Stock is convertible into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election and automatically upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- The Series D Preferred Stock is convertible into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election and automatically upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

/s/ V. Whyte, Authorized

Signatory,

GlaxoSmithKline plc

** Signature of Reporting Person

02/11/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.